Cost Analysis of Therapy on Urinary Tract Infection Inpatients in Dr. Moewardi Hospital Surakarta on 2016

Abstract

Urinary tract infection is one of the infectious diseases that occur due to the presence
of microorganisms in the urine. Urinary tract infection financing was regulated in the INA-CBG’s
rates. The study purpose was determined the conformity of real cost to the INA-CBG’s rates in
hospitalized of national health insurance patients with urinary tract infection disease in Dr.
Moewardi hospital Surakarta in 2016.
This study was an observational study using a cross sectional design. Retrospective
data collection method. Data were analyzed to see the treatment pattern of patients during
hospitalization, to find the difference in real costs with INA-CBG's rates using the one sample ttest,
and to see factors related to real costs using the bivariate correlation test.
The result showed that the treatment pattern for hospitalized patients with urinary tract
infection are using Ceftriaxone (40,8%), Cefixime (7,1%), Ceftazidime (10,2%), Ciprofloxacin
(26,5%), Levofloxacin (9,2%), Amoxicillin (3,1%), Ampicillin (1,0%), and Gentamicin (2,0%). The
analysis of real cost to the INA-CBG’s rates showed the differences between real cost and INACBG’s
rate of national health insurance patients with urinary tract infection disease.
This difference shows a positive condition, where the total real costs are lower than the INACBG's
rates. The factor related to the real cost of urinary tract infection treatment including of
LOS, secondary diagnoses, and treatment classes.